How to get retatrutide in 2026

You can’t get retatrutide with a prescription or buy it legally in October 2026. It’s an investigational drug from Eli Lilly that no regulator has approved, and Lilly says it’s legally available only to people in its clinical trials. Since June 2026, there’s one more route: a pre-approval expanded access program for some adults with severe obesity. Lilly plans to ask the FDA for approval in the first quarter of 2027.

Here’s where it stands, the legal ways to get it, and what to use while you wait.

What retatrutide is

Retatrutide is a once-weekly injection that Lilly calls a “triple hormone receptor agonist.” It acts on three receptors: GIP, GLP-1 and glucagon. For comparison, semaglutide (Wegovy) acts on GLP-1 alone, and tirzepatide (Zepbound) on GIP and GLP-1. In trials, people start at 2 mg a week and step up every four weeks to a target dose of 4 mg, 9 mg or 12 mg (Lilly).

Where retatrutide stands in October 2026

The Q1 2027 filing is Lilly’s plan, not a decision. Lilly says it is still completing the manufacturing (Chemistry, Manufacturing and Controls) data the application needs, and the FDA review takes months after a submission. Lilly has not given an approval or launch date (Lilly).

What the trials found

All three TRIUMPH trials ran 80 weeks, randomized, double-blind and placebo-controlled. These are the average weight losses Lilly reported.

Scroll sideways to see the full table

Lilly reports TRIUMPH-1 and TRIUMPH-2 as “efficacy estimand” figures, which estimate the result if everyone had stayed on treatment. FDA labels for approved drugs such as Zepbound print intent-to-treat figures, which count everyone assigned to the drug, so the numbers aren’t a like-for-like comparison. In TRIUMPH-2, A1C, a measure of blood sugar, fell 1.4 to 1.6 percentage points from a 7.7% baseline, against 0.2 on placebo.

In TRIUMPH-1, knee osteoarthritis pain scores fell by up to 73.1% in a group with knee pain, and sleep apnea events fell by up to 60.6% in a group with moderate to severe sleep apnea (Lilly).

One more trial matters for anyone weighing retatrutide against an approved drug. A Phase 3 study comparing retatrutide with tirzepatide, the drug in Zepbound, in adults with obesity (NCT06662383) lists November 2026 as its primary completion date, so head-to-head results could follow in the months after.

Side effects in TRIUMPH-1

Stomach side effects were the most common, and they rose with dose.

Scroll sideways to see the full table

At 12 mg in TRIUMPH-1, more than 1 in 10 people stopped because of side effects (Lilly). The full safety profile will be on an FDA label only if the drug is approved.

The legal ways to get retatrutide now

1. Join a clinical trial

ClinicalTrials.gov lists dozens of retatrutide studies. Most of the Phase 3 obesity trials are “active, not recruiting,” so they’ve stopped enrolling. A Phase 2 study in adults with obesity or overweight (NCT07467447) was recruiting when we checked on October 18, 2026, with primary completion expected in March 2027, and a Phase 3 master protocol in liver disease (SYNERGY-Outcomes, NCT07165028) was also recruiting. Search ClinicalTrials.gov for retatrutide, filter for recruiting studies near you, and contact the trial site. You can’t pay to join a trial, and you may be given placebo.

Before you enroll, ask the site a few questions: how likely you are to get placebo, how many visits the study needs and how long it runs, whether travel or time is reimbursed, which of your current medicines you’d have to stop, and what happens to your treatment when the study ends. The answers vary by trial, and the consent form should spell them out.

2. Ask about expanded access

Lilly posted a pre-approval expanded access program on June 5, 2026. It’s for single patients, requested by their physician, who meet all of these:

• Age 18 or older.
• Refractory obesity, defined as a BMI of 35 or more despite sticking with and tolerating treatment.
• Two or more serious or life-threatening obesity-related complications.
• Unable to join an ongoing retatrutide trial or a similar one.
• Every standard option, including bariatric surgery, discussed through shared decision-making.

Anyone with a medical reason not to take retatrutide is excluded. If you think you qualify, the request starts with your own physician, not with a website.

3. Wait for an FDA decision

If you don’t fit either route, the only legal option is to wait for the FDA to decide on Lilly’s application, which Lilly plans to submit in the first quarter of 2027.

Why you shouldn’t buy retatrutide online

Websites and “peptide” sellers have been offering retatrutide, often labeled as a lab chemical not meant for people. In August 2026, Lilly stated that “no medicine containing retatrutide has yet been approved for human use by any regulatory agency in the world” and that “it cannot be sold to consumers” (Lilly).

Lilly also cites the FDA’s positions: retatrutide “cannot be lawfully compounded,” so no licensed compounding pharmacy can legally make it for you; products labeled for lab research “are of unknown quality and may be harmful”; and “unapproved drugs sold for human use may pose significant risks for patients and are illegal.” A product bought this way has no FDA review of what is in the vial, how much, or how clean it is. We don’t list or link to any seller of retatrutide.

Approved options while you wait

Several FDA-approved medicines are available now with a prescription:

• Zepbound (tirzepatide): in SURMOUNT-1, people lost 20.9% of body weight on average at 15 mg over 72 weeks, against 3.1% on placebo (label).
• Wegovy (semaglutide): 14.9% at 2.4 mg over 68 weeks in STEP 1, and 18.8% at the 7.2 mg Wegovy HD dose over 72 weeks in STEP UP (label).
• Daily pills: the Wegovy pill and Foundayo.

Our semaglutide vs tirzepatide guide compares the two approved injections, and our brand-name GLP-1 rankings and tirzepatide provider rankings list programs that prescribe them. Prices for each are in our Zepbound cost and Wegovy cost guides.

The bottom line

As of October 2026, the only legal ways to get retatrutide are a clinical trial or, for adults with severe obesity and serious complications, a physician’s request for expanded access. Lilly plans to file for FDA approval in the first quarter of 2027, with no approval date yet. Anything sold online as retatrutide is an unapproved drug that Lilly says cannot be lawfully compounded or sold. Talk to a licensed clinician about the approved options in the meantime, and see our weight-loss hub to compare them.